Physician profile
Daniel H Donovan
NPI 1629068994
$21,219.60
in general payments reported to CMS, 2019-2025
70 companies · $5,810 in 2025
The $5,810 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,701 · 2020: $589 · 2021: $1,880 · 2022: $3,030 · 2023: $3,475 · 2024: $3,734 · 2025: $5,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,297 · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,243.82 |
| Travel and Lodging | $1,296.76 |
| Education | $478.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,966.26 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,605.18 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Heartflow, INC. | $1,526.01 | 2025 | |
| Abbvie INC. | $1,230.17 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Biogen, INC. | $1,172.06 | 2019-2025 | Vumerity, Avonex, Plegridy |
| Novartis Pharmaceuticals Corporation | $948.47 | 2019-2025 | |
| Emd Serono, INC. | $920.92 | 2019-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $835.26 | 2019-2025 | |
| Lundbeck LLC | $829.27 | 2019-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $569.19 | 2019-2024 | Qelbree, Qelbree |
| Sumitomo Pharma America, INC. | $552.98 | 2023-2024 | Aptiom |
| Genzyme Corporation | $517.83 | 2019-2025 | |
| Pfizer INC. | $517.75 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $457.26 | 2019-2025 | Rexulti, Nuedexta |
| Eisai INC. | $453.81 | 2019-2025 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.